SHC

Sotera Health has delivered a 35.0% gain over the past three years, yet its recent softer returns leave a clear question for investors who care about cash flows.

Broyhill Asset Management, a Charlotte-based firm, issued its second-quarter 2026 investor letter, which is available for download here.

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the research tools & consumables industry, including Sotera Health Company (NASDAQ:SHC) and its peers.

Sotera Health Company trades at $19.02 per share and has stayed right on track with the overall market, gaining 11.3% over the last six months. At the same time, the S&P 500 has returned 13.1%.

Sotera Health’s second quarter was marked by broad-based growth across its business units, which drove a positive market reaction.

Revenue hit $321 million with adjusted EPS up 30% year over year.

US-based investment company McIntyre Partnerships delivered flat performance in H1 2026, returning 0% gross and -1% net compared to the Russell 2000 Value Index’s 23% return. A copy of the letter can be downloaded here.

Healthcare services company Sotera Health (NASDAQ:SHC) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 9.2% year on year to $321.4 million.

Sotera Health Company’s Q2 2026 results, released on August 6, showed revenue rising to US$321.38 million and net income to US$53.64 million, with earnings per share from continuing operations increasing to US$0.19 from US$0.03 a year earlier.

Sotera Health (NASDAQ:SHC) reported second-quarter 2026 results that included 8% constant-currency revenue growth, higher adjusted EBITDA margins and an increase to its full-year revenue and adjusted EBITDA outlook.